|
Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs
|
22 September 2016 |
|
Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress
|
15 September 2016 |
|
Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp
|
29 August 2016 |
|
Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology
|
15 August 2016 |
|
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
|
03 August 2016 |
|
Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor
|
28 June 2016 |
|
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
|
15 June 2016 |
|
Novartis highlights its strong foundation for long-term, sustainable growth
|
25 May 2016 |
|
Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
|
18 May 2016 |
|
Novartis Foundation and partners launch innovative hypertension program in Vietnam
|
17 May 2016 |